Empowering Your Successful Pregnancy

Leading The Way
Innovating Preimplantation Genetic Screening (PGS) solutions to maximize the chances for a successful pregnancy.


Empowering Your Successful Pregnancy

Leading The Way
Innovating Preimplantation Genetic Screening (PGS) solutions to maximize the chances for a successful pregnancy.


ZytoGen's scientists utilize our proprietary ZytoGen Preimplantation Genetic Screening platform utilizing Next Generation Sequencing to: 

  • Increase your chance of a successful pregnancy

  • Reduce the risk of miscarriages

  • Minimize the number of repeat IVF cycles

  • Reduce the risk of an abnormal pregnancy

  • Improve selection of a healthy embryo or embryos for transfer

  • Optimize conditions for single embryo transfer (SET)

Since our inception in 2014, ZytoGen Global Genetics Institute has provided best-in-class preimplantation genetic testing for thousands of patients undergoing IVF, helping them select the healthiest embryos for a successful pregnancy.

ZytoGen Global Genetics Institute has been accredited by the College of American Pathologists (CAP).

A study [by ZytoGen’s co-founders Zhihong Yang and Jiaen Liu], published in the journal Molecular Cytogenetics, suggests that extra genetic screening increases the pregnancy rate by 65%.


Jiaen Liu, M.D., Ph.D.
Co-Founder, Chairman

>>Read Bio
Dr. Jiaen Liu is the Chairman and Co-Founder of ZytoGen Global Genetics Institute, and the Founder, CEO and Chairman of Beijing Jiaen Hospital, China's leading hospital focusing on infertility diagnosis and treatment.

Dr. Liu has earned worldwide recognition for his leadership in the field of infertility and PGD, including the world’s first baby to be born after utilization of preimplantation genetic diagnosis of DMD, the world’s first ICSI (intracytoplasmic sperm injection) application in PGD, as well as firsts in the area of testicular sperm maturation, rapid fluorescence in site hybridization (FISH) technology for pre-implantation diagnosis for sex-lined disorders, etc.

Dr. Liu earned his M.D. from Hubei Medical University Department of Medicine (now the Wuhan University School of Medicine), his M.S. from Hubei Medical University in Obstetrics and Gynecology, and his Ph.D. in Biomedical Sciences from the Brussels Free University (Belgium).

Dr. Liu served as Chief of ICSI laboratory at Brussels Free University in Belgium from 1992-1995, where he led the team responsible for the development and implementation of ICSI and PGD. From 1995-2002, he served as Director of the ICSI and PGD laboratories at the Greater Baltimore Medical Center (GBMC).

Dr. Liu received a professorship at Wuhan University in 2003. Dr. Liu has published over 76 articles in internationally renowned academic journals, and has been honored by organizations including the Belgium-Netherlands Institute of Embryology, ASRM, and ESHRE for his pioneering contributions to the field of assisted reproductive technologies.

Marcus L. Wang, Esq.
Co-Founder, President and General Manager

>>Read Bio
Marcus L. Wang, Esq. is an executive, attorney, and entrepreneur specializing in translating business concepts into profitable companies.

Executive Experience

Mr. Wang is the Co-Founder, President and General Manager of the Baltimore-based ZytoGen Global Genetics Institute.

Launched in 2014, ZytoGen utilizes next generation sequencing to drive successful pregnancy outcomes for patients worldwide through its proprietary preimplantation genetic screening platform. ZytoGen is accredited by the College of American Pathologists, the organization widely considered the global leader in laboratory quality assurance.

International Business Development

From 2010 to 2013, Mr. Wang spearheaded the development, execution, and launch of global apparel powerhouse Under Armour’s China market entry. Based in Shanghai, he managed government and corporate relations, legal, operations, staffing, marketing/branding, social media, retail operations, logistics, business development, and strategy for all of China.

Mr. Wang continues to advise U.S. businesses concerning China market entry and partnerships, providing guidance on go-to-market strategy, regulatory issues, brand development, and product localization.

Legal Credentials

From 2008 to 2010, Mr. Wang practiced corporate law at the Manhattan office of DLA Piper, one of the world’s largest law firms, where he focused on international business, M&A, infrastructure, fund formation, and restructuring.

Mr. Wang is currently licensed and admitted to practice as an attorney in the State of New York (since 2008).

Government Service

Mr. Wang currently serves as a Commissioner for the Maryland Health Care Commission, and serves on the Board of Directors for the Baltimore County Revenue Authority.

Board Service

Mr. Wang sits on the President’s Roundtable at the University of Maryland Baltimore, joining a select group of senior advisers to the President.

Mr. Wang sits on the Board of Visitors at the University of Maryland Francis King Carey School of Law, where he serves as Co-Chair of the Development Committee.

At Maryland, he is the founder of the Leadership Scholars Legacy Endowment, a scholarship fund for deserving students.

Mr. Wang sits on the Board of Trustees at Gilman School, where he serves on the Board’s Executive Committee.


Born and raised in Baltimore, Mr. Wang graduated from Gilman School (2000), earned his B.A. cum laude from Harvard University (2004), and his J.D. from the University of Maryland Francis King Carey School of Law (2008).

Mr. Wang holds a Certificate in International and Comparative Business Law from the Central University of Finance and Economics in Beijing (2007), and a Certificate in Genetics and Genomics from Stanford University (2017).


Mr. Wang is a native English speaker. He is fully fluent in Mandarin Chinese with upper/intermediate fluency in Cantonese Chinese, and conversational fluency in Burmese.


In 2011, Mr. Wang was recognized by the Maryland Daily Record as one of Maryland’s “20 in their 20s,” based on “professional accomplishment, civic involvement, and impact of achievement.”


• Northwestern Journal of International Law & Business, Vol 29, No. 2 (Spring 2009): “Dancing With The Dragon: What U.S. Parties Should Know About Chinese Law When Drafting a Contractual Dispute Resolution Clause”

• Legal Practical Education in the Era of Globalization, Intellectual Property Press, Beijing (2008): “Clinical and Legal Practical Education in the United States”
Zhihong Yang, D.V.M., Ph.D.
Co-Founder, Scientific Director

>>Read Bio
Dr. Yang serves as Scientific Director at ZytoGen and Executive Director for Assisted Reproductive Technologies (ART) and Preimplantation Genetic Diagnosis (PGD) laboratories at Pacific Reproductive Center (PRC).

Prior to joining PRC in 2000, Dr. Yang was Director for ART Lab and a full-time professor at the University of Pittsburgh, School of Medicine. In addition, Dr. Yang was invited to give lectures on professional training courses including ESHRE campus courses.

Dr. Yang studied reproductive physiology and biomedicine in the United States, Canada and China. He acquired his extensive training and clinical experiences at Colorado State University, Iowa State University, University of Montreal and University of Pittsburgh. After completion of his graduate studies and post-doctorate training, Dr. Yang performed clinical work for more than twenty years while conducting comprehensive research in reproductive physiology and assisted reproductive technologies in North America.

Dr. Yang’s research interests include preimplantation genetic screening with aCGH and NGS, time-lapse culture and evaluation of in vitro fertilized embryos and development of a chemically defined medium (CDM) for culture of oocytes and embryos. His studies have been published in numerous professional journals and presented at symposia and conferences around the world. In addition, he is a reviewer for national and international journals and conferences including American Society of Reproductive Medicine (ASRM).

As an inspector for the College of American Pathologists (CAP), Dr. Yang has performed CAP accreditation/licensing inspections on assisted reproductive laboratories including andrology, embryology and immunology throughout the United States for over a decade.

Dr. Yang is a recipient of international academic awards from the International Transfer Society (IETS) and the European Society for Human Reproduction and Embryology (ESHRE). He is a member of the ASRM, ESHRE, and the American Association of Bioanalysts (AAB).

How We Help


How We Help

ZytoGen offers

  • On-site Next Generation Sequencing analysis in CAP-accredited laboratory for whole chromosome copy number imbalances

  • Embryo analysis from single fresh or frozen cell

  • 0% failure rate


  • Board-certified High-Complexity Clinical Laboratory Director

  • Ph.D. and Master’s Degree-level Molecular Technologists

  • Responsive, 24-hour availability for patients and doctors

  • Personalized, client-focused approach


  • A normal embryo contains 23 pairs of chromosomes. 

  • Aneuploid embryos have missing or extra chromosomes.

  • The majority of pregnancies with aneuploid embryos result in miscarriage.


We help all women undergoing IVF treatment, including those with:

  • Recurrent pregnancy loss

  • Repeat implantation failure

  • History of aneuploidy pregnancy

  • Advanced maternal age ( > 35)


ZytoGen’s leaders have established a global reputation for their WORK in improving the success rate for In-Vitro Fertilization. Signature accomplishments include:

Next Generation Sequencing (NGS): 
Presentation of key research demonstrating the efficacy of NGS in PGS at the ESHRE conference in Munich, Germany in Summer 2014.

Time-Lapse Imaging: 
A 2014 study, published in BMC Medical Genomics, demonstrating the effectiveness of time-lapse incubation combined with aCGH screening over conventional incubation with traditional morphology in the selection of blastocysts for increased implantation rates.

Array Comparative Genomic Hybridization:
In 2012, ZytoGen’s co-founders provided the first direct evidence that PGS can increase the chances of a successful pregnancy.

Published in 2012 in Molecular Cytogenetics, this study was the result of the world’s first randomized clinical trial with 24Sure chromosome screening, and demonstrated the efficacy of PGS in increasing the rate of successful pregnancies following selective implantation of euploid embryos, even in younger patients with more favorable IVF outcomes.

The work of ZytoGen’s co-founders has been recognized by BBC News, the New York Times, and by key opinion leaders in the field of fertility and cytogenetics.

Click here for more information and downloads.






During the IVF process, the egg is fertilized outside the womb, resulting in an embryo. Cells from the embryo are removed through a biopsy and sent to ZytoGen for screening.
ZytoGen uses our proprietary Next Generation Sequencing process to screen the total number of chromosomes in each cell, scanning the thousands of sequences of DNA unique to each chromosome, using specialized computer software and clinical expertise to perform an analysis, and ensuring that the embryo to be transferred has the normal number of chromosomes.


ZytoGen performs Preimplantation Genetic Screening (PGS) using Next Generation Sequencing (NGS), a process that has been proven to have no adverse effects on the IVF process or the health of the baby.

As a 2012 study concluded:  "[E]mbryo biopsy does not adversely affect the health of newborn [PGS] children....[i]t is important for parents to know that [PGS] is a safe option." *

*Gallagher J. Preimplantation genetic diagnosis for IVF “is safe.” BBC News [Internet.] 2012 Jul 3. 

One study [by ZytoGen’s co-founders Zhihong Yang and Jiaen Liu], involving about 100 women under age 35 found that 71 percent of the women in the group whose embryos were tested became pregnant compared with 45.8 percent of those whose embryos were selected based only on their shape.
— The New York Times